|
1）Hasegawa K, Wakino S, Simic P, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med. 2013; 19: 1496-504
|
|
|
|
2）Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol. 2005; 6: 298-305
|
|
|
|
|
|
3）Guarente L. Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med. 2011; 364: 2235-44
|
|
|
|
|
|
4）Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A. 2003; 100: 10794-9
|
|
|
|
|
|
5）Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009; 9: 327-38
|
|
|
|
|
|
6）Gillum MP, Kotas ME, Erion DM, et al. SirT1 regulates adipose tissue inflammation. Diabetes. 2011; 60: 3235-45
|
|
|
|
|
|
7）Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 2007; 6: 759-67
|
|
|
|
|
|
8）Imai S, Yoshino J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes Metab. 2013; 15: 26-33
|
|
|
|
|
|
9）Revollo JR, Körner A, Mills KF, et al. Nampt/PBEF/visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007; 6: 363-75
|
|
|
|
|
|
10）Tao R, Wei D, Gao H, et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J Biol Chem. 2011; 286: 14681-90
|
|
|
|
|
|
11）Sun Q, Li L, Li R, et al. Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats. Ann Med. 2009; 41: 311-20
|
|
|
|
|
|
12）Fulco M, Cen Y, Zhao P, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell. 2008; 14: 661-73
|
|
|
|
|
|
13）Imai S. “Clocks” in the NAD World: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochim Biophys Acta. 2010; 1804: 1584-90
|
|
|
|
|
|
14）Ramsey KM, Yoshino J, Brace CS, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. 2009; 324: 651-4
|
|
|
|
|
|
15）Imai S. Dissecting systemic control of metabolism and aging in the NAD World: the importance of SIRT1 and NAMPT-mediated NAD biosynthesis. FEBS Lett. 2011; 585: 1657-62
|
|
|
|
|
|
16）Yoshino J, Mills KF, Yoon MJ, et al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011; 14: 528-36
|
|
|
|
|
|
17）Hasegawa K, Wakino S, Yoshioka K, et al. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun. 2008; 372: 51-6
|
|
|
|
|
|
18）Hasegawa K, Wakino S, Yoshioka K, et al. Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem. 2010; 285: 13045-56
|
|
|
|
|
|
19）Wang P, Xu TY, Guan YF, et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009; 81: 370-80
|
|
|
|
|
|
20）Song HK, Lee MH, Kim BK, et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol. 2008; 295: F1485-94
|
|
|
|
|
|
21）Kang YS, Song HK, Lee MH, et al. Visfatin is upregulated in type-2 diabetic rats and targets renal cells. Kidney Int. 2010; 78: 170-81
|
|
|
|
|